-
Gut microbiota remodeling in infection and inflammation
Eun-Kyeong Jo Chungnam National University, Republic of Korea 13:00~14:30 -
Intermittent fasting as a nutritional intervention to modulate macrophage polarization for vascular health
Kyoung-Han Kim University of Ottawa, Canada 13:20~13:40 -
Spatiotemporal immune activation drives metabolic quiescence in brown adipose tissue
Su Myung Jung Sungkyunkwan University, Republic of Korea 13:40~14:00 - Panel Discussion 14:00~14:30
-
LDL versus inflammation: what remains after aggressive lipid lowering?
Oh-sung Kwon The Catholic University of Korea, Republic of Korea 13:00~13:18 -
Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond
Sung-A Bae Yonsei University, Republic of Korea 13:18~13:36 -
Colchicine for secondary prevention in ASCVD
Dae Young Cheon Hallym University, Republic of Korea 13:36~13:54 -
Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets
Christoph J. Binder Medical University of Vienna, Austria 13:54~14:12 - Panel Discussion 14:12~14:30
-
Biobank resources for human metabolic and vascular research
Hyun Joung Lim National Institute of Health, Republic of Korea 13:00~13:20 -
Leveraging biobank platforms to study cardiometabolic physiology and disease
Heiko Bugger Graz Medical University, Austria 13:20~13:40 -
Integrative analysis of metabolic dysfunction
Young Yang Sookmyung Women\'s University, Republic of Korea 13:40~14:00 - Panel Discussion 14:00~14:30
- TBD (Presentation Title) 14:30~14:40
- TBD (Presentation Title) 14:40~14:50
- TBD (Presentation Title) 14:50~15:00
- TBD (Presentation Title) 15:00~15:10
- TBD (Presentation Title) 15:10~15:20
- TBD (Presentation Title) 15:20~15:30
- TBD (Presentation Title) 15:30~15:40
- TBD (Presentation Title) 15:40~15:50
- TBD (Presentation Title) 15:50~16:00
Chairperson(s) : Hayato Tada (Kanazawa University, Japan)
-
Refined risk assessment in FH
Sayaka Funabashi Kyorin University, Japan 14:30~14:48 - Q&A 14:48~14:52
-
Cause of death in FH
Chan Joo Lee Yonsei University, Republic of Korea 14:52~15:10 - Q&A 15:10~15:14
-
Experience on new drugs for FH: including lomitapide & evinacumab
Hayato Tada Kanazawa University, Japan 15:14~15:32 - Q&A 15:32~15:36
-
Genome editing for precision medicine
HyongBum Kim Yonsei University, Republic of Korea 15:36~15:54 - Q&A 15:54~15:58
-
The race to the bottom: intensive LDL-C lowering in very high-risk Asian patients
Ade Meidian Ambari University of Indonesia, Indonesia 14:30~14:50 -
Combination therapy in high-risk patients: early vs stepwise approach
Han Na Jung Hallym University, Republic of Korea 14:50~15:10 -
Practical approaches to statin intolerance: from clinical trials to real-world solutions
Jung-Joon Cha Korea University, Republic of Korea 15:10~15:30 - Panel Discussion 15:30~16:00
-
GLP1 RA for stroke prevention
Kang-Ho Choi Chonnam National University, Republic of Korea 14:30~14:50 -
SGLT2 inhibitor for stroke survivors
Jeong-Min Kim Seoul National University, Republic of Korea 14:50~15:10 -
GLP-1 receptor agonists in Alzheimer’s disease
Sang-Won Han Soonchunhyang University, Republic of Korea 15:10~15:30 - Panel Discussion 15:30~16:00
-
Choosing the right combination therapy: statin, ezetimibe, PCSK9 inhibitor, or beyond?
TBD (Name) TBD (Affiliation, Country) 16:10~16:28 -
Korean Fact Sheet: Current status of LDL-C control and cardiovascular risk
Ye Seul Yang Seoul National University, Republic of Korea 16:28~16:46 -
Korean Fact Sheet: Real-world utilization of lipid lowering agents
Kyu Ho Kim The Catholic University of Korea, Republic of Korea 16:46~17:04 -
Why are LDL-C targets still unmet? common errors and practical solutions in the clinic
Sang Yeub Lee Chung-Ang University, Republic of Korea 17:04~17:22 - Panel Discussion 17:22~17:40
-
Do East Asians need lower statin intensity? ethnic differences in LDL-C response and safety
Eun Jeong Cho Chung-Ang University, Republic of Korea 16:10~16:28 -
Why TG is important in Asians?
Daisaku Masuda Rinku General Medical Center, Japan 16:28~16:46 -
Genetic stratification and treatment response in Korean severe hypertriglyceridemia: a prospective multicenter registry study
Hun Jee Choe Hallym University, Republic of Korea 16:46~17:04 -
Chylomicronemia: past, present and future
Hiroaki Okazaki Teikyo University, Japan 17:04~17:22 - Panel Discussion 17:22~17:40
-
Sex differences in lymphatic function and atherosclerosis outcomes
Catherine Martel University of Montreal, Canada 16:10~16:30 -
Tirzepatide and cardiometabolic outcomes: implications of dual GLP-1/GIP agonism
Yun Kyung Cho University of Ulsan, Republic of Korea 16:30~16:50 -
Effects of SGLT2 inhibitors on lipid metabolism: mechanisms and clinical implications
Joon Hwa Hong Eulji University, Republic of Korea 16:50~17:10 - Panel Discussion 17:10~17:40
Chairperson(s) : Bum Soon Choi (The Catholic University of Korea, Republic of Korea)
Panel(s) : Eun Hui Bae (Chonnam National University, Republic of Korea)
-
Lipid abnormalities in CKD
Hong Sang Choi Chonnam National University, Republic of Korea 16:10~16:30 -
Why patients with CKD develop accelerated atherosclerosis
Cheol Ho Park Yonsei University, Republic of Korea 16:30~16:50 -
Cardiovascular prevention in CKD patients
Eun Roh Seoul National University, Republic of Korea 16:50~17:10 - Panel Discussion 17:10~17:40
